Next Article in Journal
Polymorphisms in FFAR4 (GPR120) Gene Modulate Insulin Levels and Sensitivity after Fish Oil Supplementation
Next Article in Special Issue
Variation in CYP2A6 Activity and Personalized Medicine
Previous Article in Journal
Immortalized Muscle Cell Model to Test the Exon Skipping Efficacy for Duchenne Muscular Dystrophy
Article Menu

Export Article

Open AccessFeature PaperArticle
J. Pers. Med. 2017, 7(4), 14; https://doi.org/10.3390/jpm7040014

Clinical Pharmacogenetics of Cytochrome P450-Associated Drugs in Children

1
Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA
2
Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN 37232, USA
3
Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Stephen B. Liggett
Received: 6 October 2017 / Revised: 26 October 2017 / Accepted: 26 October 2017 / Published: 2 November 2017
(This article belongs to the Special Issue Cytochrome P450 Variation in Pharmacogenomics)
Full-Text   |   PDF [453 KB, uploaded 4 November 2017]   |  

Abstract

Cytochrome P450 (CYP) enzymes are commonly involved in drug metabolism, and genetic variation in the genes encoding CYPs are associated with variable drug response. While genotype-guided therapy has been clinically implemented in adults, these associations are less well established for pediatric patients. In order to understand the frequency of pediatric exposures to drugs with known CYP interactions, we compiled all actionable drug–CYP interactions with a high level of evidence using Clinical Pharmacogenomic Implementation Consortium (CPIC) data and surveyed 10 years of electronic health records (EHR) data for the number of children exposed to CYP-associated drugs. Subsequently, we performed a focused literature review for drugs commonly used in pediatrics, defined as more than 5000 pediatric patients exposed in the decade-long EHR cohort. There were 48 drug–CYP interactions with a high level of evidence in the CPIC database. Of those, only 10 drugs were commonly used in children (ondansetron, oxycodone, codeine, omeprazole, lansoprazole, sertraline, amitriptyline, citalopram, escitalopram, and risperidone). For these drugs, reports of the drug–CYP interaction in cohorts including children were sparse. There are adequate data for implementation of genotype-guided therapy for children for three of the 10 commonly used drugs (codeine, omeprazole and lansoprazole). For the majority of commonly used drugs with known CYP interactions, more data are required to support pharmacogenomic implementation in children. View Full-Text
Keywords: pediatrics; pharmacogenomics; electronic health records; drug–gene interactions; cytochrome P450 pediatrics; pharmacogenomics; electronic health records; drug–gene interactions; cytochrome P450
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Aka, I.; Bernal, C.J.; Carroll, R.; Maxwell-Horn, A.; Oshikoya, K.A.; Van Driest, S.L. Clinical Pharmacogenetics of Cytochrome P450-Associated Drugs in Children. J. Pers. Med. 2017, 7, 14.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Pers. Med. EISSN 2075-4426 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top